Lumasiran sodium

N/A

Report date: 2025/06/04 11:47:00
NMEFirst In Class

Base Information

Drug NameLumasiran sodium
Drug Alias NamelumasiranOXLUMOALN-GO1
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceHydroxyacid oxidase 1 inhibitors
TargetsHydroxyacid oxidase 1
Therapy Area/IndicationsPrimary Hyperoxaluria Type 1Cardiovascular DiseasesRenal Insufficiency, Chronic +[6] 
Global Approved IndicationsHyperoxaluria, Primary
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/11/19
Country/TerritoryMainland China(BOAO LECHENG)BelgiumUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals IncDicerna Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRoyalty PharmaCharite University, Berlin, GermanyDicerna Pharmaceuticals Inc +[5] 
Inactive CompaniesN/A
Active IndicationsPrimary Hyperoxaluria Type 1Cardiovascular DiseasesRenal Insufficiency, Chronic +[5] 
Inactive IndicationsKidney Calculi

Other Information

ATC CodeA16AX
Related LinksN/A